Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis on a Biological Immune Response Modifier
Description: The percentage of patients with psoriasis, psoriatic arthritis, and/or rheumatoid arthritis on a biological immune response modifier whose providers are ensuring active tuberculosis prevention.
Measure ID: 337
CMS Derm Specialty Set: Yes
Topped out: No
Reporting methods: Registry/QCDR
Maximum points: 10
Measure purpose: This measure encourages tuberculosis (TB) prevention for patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis on a biological immune response modifier. Physicians should ensure active TB prevention either through yearly negative standard TB screening tests or by reviewing the patient’s history to determine if they have had appropriate management for a recent or prior positive test.
The numerator: The number of patients who have a documented negative annual TB screening or have documentation of the management of a positive TB screening test with no evidence of active tuberculosis, confirmed through use of radiographic imaging (i.e., chest x-ray, CT)
The denominator: All patients with a diagnosis of psoriasis, psoriatic arthritis, and/or rheumatoid arthritis who are on a biologic immune response modifier.
Measure calculation example
Dr. Lynch saw 42 patients during the reporting period who have psoriasis, psoriatic arthritis, rheumatoid arthritis, or any combination of the three. This is the denominator. Of the 42 patients, Dr. Lynch documented a negative annual TB screening 25 times. This is the numerator.
Quality of patient care = 25/42. Dr. Lynch has a score of 59.5% for this measure. This translates to 3.0 to 3.9 points.
Because of how this measure is structured, physicians score 3 points even if they report on only one patient. Physicians receive no additional score for reporting scores that fall below 47.06%. For example, if Dr. Lynch reported on one patient encounter, he would earn 3 points. A score of 99.9% earns 8.9 points, while a score of 100% earns 10 points. In effect, there is a gap in earned points between a nearly perfect score and a perfect score.
Examples of applicable medications to MIPS 337
|Brand name||Chemical name||Mechanism of action/Type of biologic|
|Orencia||Abatacept|| Blocks T cell activation
|Rituxan||Rituximab|| CD 20 directed antibody
|Kineret||Anakinra|| IL1 inhibitors
|Stelara||Ustekinumab|| IL-12 and IL-23 inhibitors
|Siliq||Brodalumab|| IL-17 inhibitors
|Tremfya||Guselkumab|| IL-23 inhibitors
| Simponi &
Quality measure score benchmark
CMS will award points based on a comparison of your performance rate to CMS benchmarks listed below. Reach the performance rate listed to achieve the corresponding points per measure. The maximum points you can achieve for the quality score is 45 points.
|Below 3||Decile 3||Decile 4||Decile 5||Decile 6||Decile 7||Decile 8||Decile 9||Decile 10 |
|Performance rate||1 patient||47.06 -
| 60.61 -
|96.43 - 99.99||--||100%|
|Points||3 points||3 - 3.9||4 - 4.9||5 - 5.9||6 - 6.9||7 - 7.9||8 - 8.9||9 - 9.9||10|